Biocon collaborates with Canada's Juno Pharma for diabetes and obesity treatment

On Friday, October 6, leading biotechnology company Biocon Ltd announced a strategic agreement with Juno Pharmaceuticals, a well-known Canadian specialty pharmaceutical company.

The partnership aims to introduce and market Liraglutide, a novel drug-device combination for the treatment and control of type 2 diabetes and obesity.

In accordance with the conditions of the contract, Biocon will be in charge of obtaining regulatory authorization for Liraglutide and then managing its production and supply for the Canadian market.

Juno Pharmaceuticals is recognised as one of Canada's rapidly-growing pharmaceutical companies, specialising in the production of high-value generic drugs, complex pharmaceuticals, biosimilars, and other scarce medications, all geared towards enhancing the quality of healthcare in the region.

Mark Mantel, Chief Executive Officer of Juno Pharmaceuticals, said, "Our partnership with Biocon is a significant step in our commitment to provide Canadians with high-quality, affordable medications. We are dedicated to ensuring access to more complex medicines for our patients."